5-Amino-1MQ vs MOTS-c
Both 5-Amino-1MQ and MOTS-c are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
5-Amino-1MQ
Evidence C+5-Amino-1-Methylquinolinium
A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.
View full 5-Amino-1MQ profile →MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Side-by-Side
| Attribute | 5-Amino-1MQ | MOTS-c |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — small-molecule research compound (NNMT inhibitor) | Not FDA-approved — research peptide; multiple early-phase clinical trials |
| Typical Dose | 50–150 mg orally daily (research-only) | 5–10 mg, 2–3 times weekly (subcutaneous) |
| Clinics Indexed | 31 | 22 |
| Categories | fat-loss, longevity | metabolic, longevity |
Key reported benefits — 5-Amino-1MQ
- ✓NNMT inhibition
- ✓Fat-mass reduction (preclinical)
- ✓Muscle stem-cell support
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.